NVAX NOVAVAX INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1000694 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-61.3%
TTM net income YoY-122.5%
TTM EPS YoY-125.9%
Revenue 3-yr CAGR-26.8%
Net income 3-yr CAGR—
Margins
Gross margin78.0%
Operating margin-21.2%
Net margin-18.6%
FCF margin-59.2%
EBITDA margin-17.7%
Returns
ROE—
ROA-7.4%
ROIC (approx.)—
Asset turnover0.40x
Leverage & solvency
Liabilities / assets124.4%
Debt / equity—
Current ratio2.15x
Interest coverage-4.01x
Cash quality & payout
Operating cash flow / net income3.11x
Accruals ratio15.7%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.12B | $682.16M |
| Cost of revenue | $73.04M | $202.74M |
| Gross profit | $1.05B | $479.42M |
| R&D expense | $342.32M | $391.17M |
| SG&A expense | $157.48M | $337.19M |
| Operating income | $452.80M | -$248.93M |
| Interest expense | $22.55M | $20.07M |
| Pretax income | $442.17M | -$176.62M |
| Income tax | $1.86M | $10.88M |
| Net income | $440.30M | -$187.50M |
| EBITDA | $480.80M | -$200.93M |
| EPS (basic) | 2.72 | -1.23 |
| EPS (diluted) | 2.58 | -1.23 |
| Weighted avg. shares (diluted) | 173.10M | 152.19M |
| Balance sheet | ||
| Cash & equivalents | $240.63M | $545.29M |
| Short-term investments | $494.45M | $392.89M |
| Inventory | $11.54M | $8.75M |
| Current assets | $978.28M | $1.13B |
| PP&E, net | $44.80M | $138.41M |
| Goodwill | $113.46M | $107.48M |
| Total assets | $1.18B | $1.56B |
| Current liabilities | $459.95M | $1.15B |
| Long-term debt | $244.21M | — |
| Total debt | $244.21M | — |
| Total liabilities | $1.30B | $2.18B |
| Shareholders' equity | -$127.75M | -$623.84M |
| Net debt | $3.58M | — |
| Shares outstanding | 162.58M | 160.42M |
| Cash flow statement | ||
| Operating cash flow | -$244.63M | -$87.26M |
| Capital expenditure | $5.56M | $13.06M |
| Free cash flow | -$250.19M | -$100.32M |
| Investing cash flow | -$78.27M | -$204.04M |
| Financing cash flow | $27.74M | $260.58M |
| Depreciation & amortization | $28.00M | $48.00M |
| Stock-based compensation | $36.02M | $48.15M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.